Slide 1: Dexcom earnings presentation
bpexcom ; y l a Nt if iu ai Dexcom earnings | dees
Slide 2: Safe harbor statement
Safe harbor statement This presentation contains “forward-looking statements" that are based on our management's beliefs and assumptions and on information available to management as of April 25, 2024. We intend for such forward-looking statements to be covered by the safe harbor provisions for forw
Slide 3: First quarter 2024
First quarter 2024 idl © Key Financial Strategic $921 million in revenue Highlights Highlights 25% organic revenue growth! Generated more than 600 basis Received FDA clearance for Stelo and (24% US; 26% INT'L?) points of operating expense leverage direct-to-watch feature compared to Q1'23 Launched D
Slide 4: First quarter performance
First quarter performance Total Revenue & Organic Growth Rate! Non-GAAP Gross Profit and Margin* ($m™) ($MM) $1,200 $975 $1,035 $750 $630 $664 $1,000 $741 $871 $921 $600 $470 $553 $569 $600 $450 $400 $300 $200 | faa +26% +26% +26% +25% ESM 63.4% 63.5% 64.7% 64.2% 61.8% $0 $0 Q123 Q2'23 Q3'23 Q4'23 Q
Slide 5: 2024 Guidance as of April 25, 2024
2024 Guidance as of April 25, 2024 2024 Annual Revenue and Profitability Guidance Revenue USD 4.20-4.35 billion Non-GAAP Gross Profit Margin ~63-64% Non-GAAP. Operating Margin Adjusted EBITDA Margin* “Adjusted EBITDA defined as EBITDA adjusted to exclude non-recurring charges and stock-based compens
Slide 6: Appendix: Revenue Data and GAAP Reconciliations
bexcom Appendix Revenue Data and GAAP Reconciliations
Slide 7: GAAP to non-GAAP reconciliation
Three Months Ended March 31, Three Months Ended March 31, (In millions) 2024 2023 (In millions, except per share data) 2024 2023 GAAP gross profit $ 561.9 $ 462.6 GAAP net income $ 146.4 $ 48.6 Amortization of intangible assets (1) 7.2 7.2 Amortization of intangible assets (1) 10.4 9.0 Non-GAAP gros
Slide 8: Revenue Metrics By Component
Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Revenue Metrics By Component Sensor & Other Revenue (millions) (1) (2) $ 424.3 $ 494.5 $ 547.9 $ 598.6 $ 543.2 $ 597.7 $ 666.6 $ 714.8 $ 651.9 $ 778.0 $ 873.8 $ 947.0 $ 854.3 Year over year growth 31% 36% 35% 29% 28% 21% 2
Slide 9: Revenue Metrics By Geography
Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Revenue Metrics By Geography US Revenue (millions) $ 381.2 $ 461.5 $ 489.6 $ 517.1 $ 451.2 $ 511.0 $ 573.4 $ 606.4 $ 526.0 $ 616.6 $ 713.6 $ 769.1 $ 653.2 Year over year growth 30% 26% 23% 15% 18% 11% 17% 17% 17% 21% 24% 2
Slide 10: Organic Revenue
Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 (1) Organic Revenue INT'L Revenue - Reported $ 123.8 $ 133.6 $ 160.6 $ 181.1 $ 177.6 $ 185.2 $ 196.2 $ 208.8 $ 215.5 $ 254.7 $ 261.4 $ 265.4 $ 267.8 Impact of Acquired or Divested Revenue 0.0 0.0 (10.7) (14.9) (13.0) (16.2
Slide 11: Non-GAAP measure definitions
DexCom, Inc. Amortization of intangible assets - We are required under GAAP to record the fair values of the intangible assets of the entity on our balance sheet and amortize them over their useful lives. We exclude these non-cash amortization charges related to acquired intangible assets from our n